Fatty acids and neuropsychiatric disorders

Management of depression in patients with coronary artery disease: A systematic review

Depression is an independent risk factor for coronary artery disease (CAD). Both illnesses contribute significantly to the global burden of disease. This systematic literature review examines treatment interventions for CAD patients with comorbid depression. We systematically reviewed The Cochrane Library, MEDLINE, EMBASE, PsycINFO, PUBMED, CINAHL and the ISRCTN Registry for English language randomised control trials investigating treatment interventions for depression in adults with CAD and comorbid depression. Data extracted included author name(s), year published, number of participants, enrolment criteria, depression definition/measures (standardised interviews, rating scales), description of control arms and interventions (psychotherapy and/or medications), randomisation, blinding, follow-up duration, follow-up loss, depression scores and medical outcome. The database search revealed 4464 articles. The review yielded 19 trials. Antidepressant and/or psychotherapy did not significantly influence CAD outcomes in the overall population. There was no difference between antidepressant use and aerobic exercises. Psychological interventions and pharmacological interventions provide small effect on depression outcomes in CAD patients. Patient autonomy in choice of treatment is associated with greater depression treatment satisfaction, but the majority of studies are underpowered. More research is required to explore the role of neurostimulation treatment, complementary and alternative treatments.

Treatment for tobacco smoking: a new alternative?

Smoking is a very common addiction and is associated with several kinds of diseases including different forms of cancer. Nicotine is the only substance present in cigarettes that can cause dependence. There are pharmacological treatments available to smoking cessation, but all of them are associated with side effects and low efficacy. Therefore, the development of new strategies and treatments is necessary. A possibility is the supplementation with polyunsaturated fatty acids (PUFAs) of the omega 3 series. It is known that low concentration of omega 3 can affect the dopaminergic neurotransmission, resulting in hypofunctioning of the mesocortical system. This system controls the mesolimbic system, associated in rewarding and dependence mechanisms. New perspectives of treatment focus on the reestablishment of the omega 3 levels, having as a result the normalization of the dopaminergic system and the reduction of the negative symptoms of withdrawal.

Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies

PURPOSE OF REVIEW

Schizophrenia is a severe mental disorder with substantial genetic vulnerability. This review discusses recent neuroimaging studies reporting on impairment in brain functioning relevant to language processing in individuals with schizophrenia and those who are at a genetic risk for its development.

RECENT FINDINGS

Studies have shown that schizophrenia is associated with deficits in language function, as well as structural and functional abnormalities in brain regions that are involved with language perception and processing. Individuals who are at genetic high risk for schizophrenia also have structural and functional deficits in brain pathways for language processing. These studies consistently suggest that the normal pattern of left hemisphere dominance of language processing is significantly disturbed.

SUMMARY

This review suggests that future studies should examine the underlying mechanism for producing this disturbance in language processing and that prospective studies should be carried out that aim to follow individuals over time to determine whether these anomalies eventually lead to clinical symptoms of schizophrenia.